Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb 15;65(4):304-12.
doi: 10.1016/j.biopsych.2008.07.024. Epub 2008 Sep 18.

Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease

Affiliations

Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease

Colm Cunningham et al. Biol Psychiatry. .

Abstract

Background: Chronic neurodegeneration results in microglial activation, but the contribution of inflammation to the progress of neurodegeneration remains unclear. We have shown that microglia express low levels of proinflammatory cytokines during chronic neurodegeneration but are "primed" to produce a more proinflammatory profile after systemic challenge with bacterial endotoxin (lipopolysaccharide [LPS]).

Methods: Here, we investigated whether intraperitoneal (IP) challenge with LPS, to mimic systemic infection, in the early stages of prion disease can 1) produce exaggerated acute behavioral (n = 9) and central nervous system (CNS) inflammatory (n = 4) responses in diseased animals compared with control animals, and 2) whether a single LPS challenge can accelerate disease progression (n = 34-35).

Results: Injection of LPS (100 microg/kg), at 12 weeks postinoculation (PI), resulted in heightened CNS interleukin-1 beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and interferon-beta (IFN-beta) transcription and microglial IL-1beta translation in prion-diseased animals relative to control animals. This inflammation caused exaggerated impairments in burrowing and locomotor activity, and induced hypothermia and cognitive changes in prion-diseased animals that were absent in LPS-treated control animals. At 15 weeks PI, LPS (500 microg/kg) acutely impaired motor coordination and muscle strength in prion-diseased but not in control animals. After recovery, these animals also showed earlier onset of disease-associated impairments on these parameters.

Conclusions: These data demonstrate that transient systemic inflammation superimposed on neurodegenerative disease acutely exacerbates cognitive and motor symptoms of disease and accelerates disease progression. These deleterious effects of systemic inflammation have implications for the treatment of chronic neurodegeneration and associated delirium.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Acute sickness behavioral responses to intraperitoneal LPS. (A) Weight burrowed over 2 hours by C57BL/6 mice at baseline, 2 hours, 24 hours, and 48 hours post-IP challenge with 100 μg/kg LPS or sterile saline. ME7 and NBH animals were 12 weeks postinoculation with the ME7 murine scrapie strain or normal brain homogenate, respectively. Statistical significance was determined by planned comparisons by one-way ANOVA with Bonferroni post hoc test at 24 hours. (B) Distance traveled in an open field by the same animals at baseline, 5 hours, 24 hours, and 48 hours postchallenge with LPS. Statistical significance was determined by planned comparisons by one-way ANOVA with Bonferroni post hoc test at 5 hours. (C) Core body temperature of the same animals at −24, 0, 5, and 24 hours postchallenge with LPS or saline. Planned comparison by one-way ANOVA at 5 hours was performed. All data are plotted as mean ± SEM and n = 9 in all groups. *p < .05. ANOVA, analysis of variance; IP, intraperitoneal; LPS, lipopolysaccharide; NBH, normal brain homogenate.
Figure 2
Figure 2
Inflammatory changes post-LPS at 12 weeks. Relative mRNA expression for treatment groups NBH + saline, NBH + LPS 100 μg/kg, ME7 + saline, and ME7 + LPS 100 μg/kg for (A) IL-1β, (B) TNF-α, and (C) IFN-β. In all cases, n = 4 for all groups except ME7 + saline (n = 5). Significant interactions of disease and acute treatment by two-way ANOVA are denoted by two asterisks (**) (IL-1β p < .0001; TNF-α p = .0013) and a significant difference between ME7 + LPS and all other groups by one-way ANOVA is denoted by one asterisk (*). (D) COX-2 staining (brown) both around the vasculature and in the parenchyma after IP challenge of NBH animals with LPS. (E) Increased COX-2 positive cells, with respect to NBH, in the parenchyma of ME7 animals treated with saline. (F) COX-2 positive stained cells in both the parenchyma and around the vasculature of ME7 animals challenged with LPS. (G-I) IL-1β positive staining in microglial cells in the hippocampus of ME7 animals challenged IP with LPS (I) compared with an absence of this staining in ME7 per se (H) and in NBH animals treated with LPS (G). Scale bar represents 100 μm (D, F) and 40 μm (G-I). ANOVA, analysis of variance; COX-2, cyclooxygenase-2; IFN-β, interferon-beta; IL-1β, interleukin-1 beta; IP, intraperitoneal; LPS, lipopolysaccharide; mRNA, messenger RNA; NBH, normal brain homogenate; TNF-α, tumor necrosis factor-alpha.
Figure 3
Figure 3
Spatial learning in the paddling Y-maze: normal and prion-diseased animals and hippocampal-lesioned and sham-operated control animals. (A) Cognitive performance of animals in the paddling Y-maze at 12 weeks postinoculation with ME7 (100 μg/kg LPS or saline) and NBH (500 μg/kg LPS or saline) 3 to 7 hours after IP challenge. This plot represents the total number of incorrect trials (out of 10) by each treatment group. Each animal is shown as an individual point and the median is illustrated by the bar. Kruskal-Wallis ANOVA revealed a difference in the medians (p < .0001) and pairwise comparisons showed ME7 + LPS to be significantly different to all other groups (**), n = 23 in the case of both NBH groups and n = 24 for both ME7 groups. (B) The same data are plotted as two successive blocks of five trials, showing the average number of arms entered including the final correct one. Block 2 is compared with block 1 by Student t tests in all cases (*p < .05). The average number of arms entered in block 1 by each group was also compared by ANOVA with Bonferroni post hoc test (*p < .05, **p < .01). (C) Hippocampal-lesioned animals compared with sham-operated control animals tested across two blocks of five trials on the same paddling Y-maze. A repeated measures ANOVA analysis shows a significant effect of treatment (F = 10.78, p = .0039, df = 1,19) and of trial (F = 3.54, p = .0005, df = 9,171). ANOVA, analysis of variance; IP, intraperitoneal; LPS, lipopolysaccharide; NBH, normal brain homogenate.
Figure 4
Figure 4
Acute effects on motor tasks induced by LPS in normal and prion-diseased animals. (A) Performance on a horizontal bar at 14 weeks postinoculation with ME7 or NBH, followed by performance at 6 hours, 24 hours, and 1 week after IP LPS (500 μg/kg) or saline challenges in these animals. Data were plotted as mean ± SEM and analyzed by repeated measures ANOVA Bonferroni post hoc tests (p < .05 between ME7 + LPS and NBH + LPS, n = 13–15 for all groups). (B) Replot of the 6-hour post-LPS time point showing the median and full range of values. These data were compared by Kruskal-Wallis test with Dunn's post hoc test (*p < .05). (C) Performance on an inverted screen at the same time points as described above. Data are shown as mean ± SEM and were analyzed by repeated measures ANOVA with Bonferroni post hoc test (p < .001 between ME7 + LPS and NBH + LPS, n = 13–15 for all groups). (D) Replot of the inverted screen 6-hour post-LPS time point showing the median and full range of values. These data were compared by Kruskal-Wallis test with Dunn's post hoc test (*p < .05). ANOVA, analysis of variance; IP, intraperitoneal; LPS, lipopolysaccharide; NBH, normal brain homogenate.
Figure 5
Figure 5
Longitudinal effects of LPS at 14 to 15 weeks on the progression of prion disease. (A) Performance on the horizontal bar for 6 successive weeks post-IP challenge with LPS (500 μg/kg) or saline at 15 weeks postinoculation with ME7 or NBH. Data are shown as mean ± SEM (n = 25 for NBH + LPS, n = 34 for ME7 + Saline, and n = 35 for ME7 + LPS). ME7 + LPS and ME7 + saline data were compared by repeated measures ANOVA across the 6 weeks shown and showed both main effects of treatment and time and an interaction of treatment and time (* denotes p = .0166 for the main effect of treatment). (B) Performance of the same animals on the inverted screen for 5 successive weeks post-IP challenge with LPS (500 μg/kg) or saline. Data are shown as mean ± SEM (n = 25 for NBH + LPS, n = 34 for ME7 + Saline, and n = 35 for ME7 + LPS). ME7 + Saline and ME7 + LPS data were compared by repeated measures ANOVA across the 5 weeks shown and showed both main effects of treatment and time and an interaction of treatment and time (** denotes p = .0147 for the main effect of treatment). (C) Open field activity for 7 successive weeks post-IP challenge with LPS 500 μg/kg. Data are shown as mean ± SEM (n = 19, n = 20). Repeated measures ANOVA of ME7 groups showed main effects of time and treatment (* denotes p = .0044 for the main effect of treatment). ANOVA, analysis of variance; IP, intraperitoneal; LPS, lipopolysaccharide; NBH, normal brain homogenate.

Similar articles

Cited by

References

    1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383–421. - PMC - PubMed
    1. Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. BMJ. 2003;327:128. - PMC - PubMed
    1. Aisen P.S. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002;1:279–284. - PubMed
    1. Firuzi O., Pratico D. Coxibs and Alzheimer's disease: Should they stay or should they go? Ann Neurol. 2006;59:219–228. - PubMed
    1. McGeer P.L., McGeer E.G. NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28:639–647. - PubMed

Publication types

MeSH terms

Substances